ISO 20387:2018 - Biobanking General Requirements Lead Implementer Free Practice Test — 30 Questions

Question 1

An auditor reviewing a biobank\'s adherence to ISO 20387:2018 identifies a discrepancy where certain biological samples lack detailed provenance information, including specific collection dates and donor consent status, within the primary sample management system. This omission is traced back to a lack of standardized data entry protocols for field collection teams and an absence of mandatory data validation checks before sample registration. Considering the fundamental principles of biobanking quality management as outlined in the standard, what is the most significant implication of this deficiency for the biobank\'s overall compliance and operational integrity?

Accepted Answer

Compromised traceability and potential inability to demonstrate adherence to consent requirements, impacting the ethical and legal use of samples.

Question 2

A biobank specializing in human tissue samples for rare disease research has amassed a significant collection over several years. A new, groundbreaking research project is proposed that requires access to samples from individuals diagnosed with a specific subtype of a rare neurological disorder. Upon reviewing the existing consent forms for a portion of the relevant samples, it\'s discovered that while general consent for future research was obtained, it did not explicitly detail the specific type of genetic analysis planned for this new project, which involves advanced genomic sequencing with potential implications for familial genetic predispositions. According to ISO 20387:2018, what is the most appropriate course of action for the biobank to ensure compliance and ethical handling of these samples for the proposed research?

Accepted Answer

Initiate a process to re-contact the donors of the relevant samples to obtain specific, informed consent for the proposed genetic analysis.

Question 3

A newly established biobank, focusing on rare genetic disorders, is developing its operational framework. The lead implementer is tasked with ensuring the biobank\'s quality management system (QMS) fully aligns with ISO 20387:2018. Considering the long-term preservation and research utility of highly valuable, often limited, biological samples, which of the following best describes the fundamental approach the QMS must adopt to guarantee the integrity and traceability of these materials throughout their entire lifecycle, from collection to eventual use or disposal?

Accepted Answer

Implement a comprehensive, documented system of controls and procedures that proactively addresses potential risks at every stage of the biological material lifecycle, ensuring continuous monitoring, validation, and traceability.

Question 4

A biobank, operating under ISO 20387:2018, has received a collection of human tissue samples. The accompanying documentation clearly states that the donors provided consent for the initial diagnostic purpose only and explicitly prohibited any future research use. As the Lead Implementer, what is the most appropriate course of action to ensure compliance with both the donor\'s wishes and applicable data protection regulations, such as GDPR, when a researcher requests these samples for a novel study?

Accepted Answer

Segregate these samples and their associated data, ensuring they are not made available for any research activity that deviates from the original consent, and establish a protocol for handling future requests that strictly adheres to these limitations.

Question 5

A biobank operating under ISO 20387:2018 discovers that a critical reagent used for sample preservation was inadvertently exposed to suboptimal temperature conditions for a period of 48 hours, potentially compromising its efficacy. This deviation was noted by a senior technician during routine quality checks. What is the immediate and most compliant course of action for the biobank\'s quality manager, according to the principles of the standard?

Accepted Answer

Initiate the documented nonconformity and corrective action process, including root cause analysis and effectiveness review of implemented actions.

Question 6

A newly established biobank, focused on rare plant genetic resources, is undergoing its initial internal audit against ISO 20387:2018. The audit team identifies that while the biobank has comprehensive Standard Operating Procedures (SOPs) for sample collection, processing, and storage, there is a lack of formal, documented evidence of ongoing competency assessment for personnel involved in cryopreservation techniques. The biobank director argues that the team members are highly experienced botanists and have received extensive on-the-job training. Which aspect of the biobank\'s operational framework, as stipulated by ISO 20387:2018, is most critically deficient in this scenario, potentially impacting the integrity and fitness-for-purpose of its collections?

Accepted Answer

Formalized and documented personnel competency assessment and ongoing training records.

Question 7

A newly established biobank, focused on rare plant genetic resources, is seeking full accreditation under ISO 20387:2018. The biobank\'s operational scope includes collection, processing, storage, and distribution of diverse plant samples. During an internal audit, it was identified that while individual SOPs exist for each process, there is a lack of overarching procedural integration and a formalized system for identifying, assessing, and mitigating potential risks to sample integrity and data accuracy across the entire workflow. The audit report also highlighted inconsistencies in record-keeping practices between different departments. Considering the foundational requirements of the standard, what is the most critical deficiency that needs immediate attention to ensure compliance and operational excellence?

Accepted Answer

The absence of a fully integrated Quality Management System encompassing risk management and comprehensive, consistent documentation across all biobanking activities.

Question 8

A biobank operating under ISO 20387:2018 discovers that a batch of cryopreserved human plasma samples, intended for proteomic research, has experienced a temperature excursion during routine inventory checks, potentially compromising their structural integrity and analyte stability. The biobank\'s quality manager must decide on the immediate course of action for these affected samples. Which of the following actions best aligns with the principles of managing nonconforming outputs as stipulated by the standard?

Accepted Answer

Segregate the affected plasma samples and initiate a root cause analysis to determine the extent of the temperature excursion and its impact on sample quality, followed by a documented decision on their disposition.

Question 9

A biobank operating under ISO 20387:2018 receives a batch of human plasma samples. During routine quality control testing, it is discovered that a significant portion of these samples have undergone freeze-thaw cycles, rendering their protein integrity compromised and making them unsuitable for their intended downstream proteomic analysis. The biobank\'s quality manager must decide on the immediate course of action to maintain compliance with the standard. Which of the following actions best aligns with the requirements for managing non-conforming outputs as stipulated by ISO 20387:2018?

Accepted Answer

Segregate the compromised plasma samples and dispose of them, documenting the deviation and the disposal rationale.

Question 10

When establishing a comprehensive quality management system in accordance with ISO 20387:2018, which fundamental principle underpins the biobank\'s commitment to ensuring the integrity and reliability of its operations and biobanked materials throughout their lifecycle?

Accepted Answer

The systematic development and application of documented procedures for all biobanking activities, coupled with a proactive approach to risk identification and mitigation, and a commitment to continuous improvement.

Question 11

A biobank specializing in rare plant genetic resources is undergoing an audit to ensure compliance with ISO 20387:2018. The audit team has identified a discrepancy in the documentation for a batch of seeds collected from a remote alpine region. While the collection date, location, and collector are recorded, there is no explicit mention of the environmental conditions at the time of collection or the specific methodology used for immediate post-collection stabilization before transport to the main facility. The biobank\'s quality manager argues that the standard\'s emphasis on traceability and fitness for purpose is met through the existing records and the general training of their field personnel. However, the audit team points to the need for detailed procedural adherence and the potential impact of unrecorded environmental factors on seed viability and genetic integrity. Considering the principles of ISO 20387:2018, what is the most critical deficiency in the biobank\'s documentation and procedural control in this scenario?

Accepted Answer

Lack of detailed records regarding the immediate post-collection stabilization procedures and environmental conditions at the collection site, which impacts the ability to fully assess fitness for purpose and potential degradation pathways.

Question 12

A biobank accredited to ISO 20387:2018 receives a shipment of human blood samples for storage. Upon initial inspection, it is noted that the anticoagulant in one of the collection tubes appears to have precipitated, rendering the sample potentially unsuitable for downstream genomic analysis. The biobank\'s standard operating procedure for sample receipt, aligned with the standard\'s requirements for managing human biological material, outlines a specific protocol for handling such discrepancies. What is the most appropriate immediate action for the biobank\'s quality manager to ensure compliance with the standard?

Accepted Answer

Quarantine the affected sample, initiate an investigation into the cause of anticoagulant precipitation, and document the findings and the decision regarding the sample's disposition.

Question 13

A biobank operating under ISO 20387:2018 discovers that a batch of human plasma samples, intended for a specific cancer research project, was inadvertently processed using a different anticoagulant than specified in the collection protocol. This deviation was identified during the quality control check before sample distribution. As the Lead Implementer, what is the most critical immediate action to ensure compliance and mitigate potential impact on research integrity?

Accepted Answer

Segregate the affected batch of plasma samples and initiate a thorough investigation into the root cause of the anticoagulant mix-up, documenting all findings and implementing immediate corrective actions to prevent recurrence.

Question 14

A biobank operating under ISO 20387:2018 discovers that a batch of human plasma samples, intended for proteomic research, exhibits significantly lower than expected levels of a key biomarker due to a temperature excursion during transport. The biobank\'s quality manager needs to determine the most appropriate course of action according to the standard\'s requirements for managing non-conforming biobanking material. Which of the following actions best aligns with the principles outlined in ISO 20387:2018 for handling such a situation?

Accepted Answer

Segregate the affected plasma samples, document the temperature excursion and its impact on the biomarker levels, investigate the root cause of the transport issue, and decide on the disposition of the samples based on their usability for the intended research.

Question 15

A biobank, aiming for ISO 20387:2018 certification, is developing its standard operating procedures for the acquisition of human tissue samples from various clinical sites. The lead implementer is reviewing the draft procedures for the collection phase. Which of the following aspects, when incorporated into the collection procedures, would most directly align with the fundamental principles of ISO 20387:2018 regarding sample integrity and traceability, while also acknowledging relevant external governance?

Accepted Answer

Detailed protocols for sample stabilization, immediate labeling with unique identifiers, and recording of all donor-related information in a secure, auditable database, ensuring compliance with local health data privacy regulations.

Question 16

A biobank, certified under ISO 20387:2018, conducts an internal audit and discovers a batch of human tissue samples that were collected for a specific research project. These samples are missing unique identifiers and their associated collection metadata is incomplete, hindering their traceability. The audit report flags this as a major non-conformity. As the Lead Implementer responsible for the biobank\'s quality management system, what is the most effective corrective action to address this systemic issue and ensure future adherence to the standard\'s requirements for sample integrity and traceability?

Accepted Answer

Revise and reinforce the standard operating procedures for sample accessioning and data recording, and implement enhanced training for personnel involved in these processes.

Question 17

A biobank accredited to ISO 20387:2018 is collaborating with an international research consortium on a novel cancer therapy. This collaboration involves the transfer of a significant cohort of cryopreserved human tumor tissue samples. The receiving institution has advanced analytical capabilities but operates under different national data privacy regulations than the originating country. What is the most critical prerequisite for the biobank to ensure before initiating this transfer to maintain compliance with the standard and safeguard the integrity and ethical handling of the biological material?

Accepted Answer

Conducting a comprehensive risk assessment that evaluates potential impacts on sample integrity, viability, and traceability, coupled with a formal agreement detailing handling, storage, and data sharing protocols that respects all applicable legal and ethical frameworks.

Question 18

Following the identification of a significant deviation in the temperature control of a cryopreservation unit, which led to a potential compromise in the viability of several stored biological samples, a biobank\'s Quality Manager has implemented a series of corrective actions. These actions included recalibrating the unit, updating the monitoring protocol, and retraining staff on emergency procedures. What is the subsequent critical step required by ISO 20387:2018 to ensure the effectiveness of these implemented measures?

Accepted Answer

Conduct a follow-up audit to verify the sustained effectiveness of the corrective actions and the updated protocols.

Question 19

A biobank operating under ISO 20387:2018 encounters a situation where a critical -80°C freezer experiences an unexpected power interruption, leading to a temperature excursion. The biobank\'s quality management system mandates a rigorous response. Which of the following actions best aligns with the standard\'s requirements for managing such a critical event to ensure the continued integrity and traceability of the affected biological samples?

Accepted Answer

Immediately initiate a full impact assessment of the temperature excursion on all samples within the affected freezer, document the deviation and the assessment findings, and implement appropriate corrective and preventive actions based on the assessment results.

Question 20

A biobank operating under ISO 20387:2018 experiences a documented temperature excursion in a critical -80°C freezer storing valuable human tissue samples. The excursion lasted for 4 hours, exceeding the acceptable deviation threshold by 2°C. The biobank\'s quality manager needs to determine the most appropriate immediate and long-term response in accordance with the standard\'s requirements for managing nonconforming outputs and ensuring the integrity of biological material. Which course of action best reflects the principles and requirements of ISO 20387:2018 for this situation?

Accepted Answer

Immediately initiate a formal deviation investigation, including a root cause analysis of the temperature fluctuation, assess the impact on the affected samples, and implement corrective and preventive actions to mitigate future occurrences.

Question 21

A newly established biobank, aiming for ISO 20387:2018 certification, is developing its operational framework. The leadership team is debating the most critical element for ensuring the integrity and fitness-for-purpose of its biological collections and associated data throughout their lifecycle, from acquisition to eventual distribution or disposal. They are considering various aspects of their planned operations. Which of the following represents the most encompassing and fundamental requirement for achieving this objective in accordance with the standard?

Accepted Answer

The establishment and rigorous adherence to a comprehensive Quality Management System that integrates documented procedures, validated processes, staff competency, and continuous improvement mechanisms.

Question 22

A biobank, certified under ISO 20387:2018, is tasked with establishing a new collection protocol for a rare extremophile microorganism discovered in a deep-sea hydrothermal vent. Existing standard operating procedures (SOPs) are not fully applicable due to the unique biological characteristics and potential unknown hazards of this organism. As the Lead Implementer, what is the most critical action to ensure compliance with the standard\'s requirements for personnel competence in this novel situation?

Accepted Answer

Develop and implement a targeted training program for all involved personnel focusing on the specific handling, containment, and risk assessment of the extremophile, alongside a competency validation process before commencing collection.

Question 23

A biobank specializing in rare plant genetic resources is undergoing an audit against ISO 20387:2018. The audit team has identified a potential gap in the biobank\'s operational framework, specifically concerning the assurance of long-term viability and genetic integrity of cryopreserved seeds. While the biobank has documented protocols for cryopreservation and storage, the audit highlights a lack of explicit, verifiable procedures for periodically assessing the germination rates and genetic stability of a representative subset of the stored seed collection, particularly for samples stored for over a decade. What fundamental aspect of ISO 20387:2018 is most directly challenged by this finding, requiring a proactive and systematic approach to address the long-term fitness for purpose of the biological material?

Accepted Answer

Ensuring the continuous monitoring and validation of storage conditions and the periodic assessment of biological material viability to confirm ongoing fitness for purpose.

Question 24

A newly established biobank, aiming for ISO 20387:2018 compliance, is developing its operational framework. The lead implementer is tasked with defining the foundational elements of their quality assurance strategy. Considering the standard\'s emphasis on consistent and reliable operations, which of the following represents the most critical initial step in establishing the biobank\'s quality management system?

Accepted Answer

Developing and documenting comprehensive standard operating procedures (SOPs) for all core biobanking processes, including sample accessioning, storage, and distribution.

Question 25

When a critical temperature excursion is detected in a long-term cryogenic storage unit housing valuable human biospecimens, what is the most comprehensive and effective approach for a biobank\'s Quality Manager, acting as a Lead Implementer for ISO 20387:2018, to manage this nonconformity and ensure future compliance?

Accepted Answer

Initiate a thorough root cause analysis, implement immediate corrective actions to stabilize the temperature, document all findings and actions, and conduct a follow-up verification of the corrective actions' effectiveness.

Question 26

A biobank, established under ISO 20387:2018, has collected human biological samples and associated clinical data from a cohort of participants for a project investigating a specific rare disease. Years later, a new research initiative proposes to use a subset of these samples and data to study a completely unrelated genetic predisposition. The original consent form obtained from participants was broad, stating that samples and data could be used for \"research related to health and disease.\" However, it did not specifically mention the new area of investigation. As the Lead Implementer, what is the most appropriate course of action to ensure compliance with ethical guidelines and data protection regulations?

Accepted Answer

Seek re-consent from the original participants or their legal representatives for the new research scope, clearly explaining the intended use of their biological material and associated data.

Question 27

Consider a biobank established to preserve endangered plant genetic resources. During an audit, it is discovered that while detailed Standard Operating Procedures (SOPs) exist for all critical processes, the biobank has not formally documented a systematic approach to identify, assess, and mitigate potential risks that could compromise the viability of the stored germplasm. This oversight extends to a lack of proactive measures for environmental control failures or unexpected power outages affecting the cold storage units. Based on the principles of ISO 20387:2018, what fundamental aspect of the biobank\'s operational framework requires immediate enhancement to align with the standard\'s general requirements for quality and integrity?

Accepted Answer

The establishment and integration of a comprehensive risk management system within the Quality Management System.

Question 28

A large research institution\'s biobanking facility, which has been operating under ISO 20387:2018 principles, is undergoing an acquisition by a multinational biobanking conglomerate. The conglomerate plans to integrate the acquired facility\'s sample collection and associated data into its global network. What is the primary requirement for the acquiring conglomerate concerning the traceability of the biological samples and their associated data during this integration process, as stipulated by ISO 20387:2018?

Accepted Answer

Ensuring the complete transfer and continued maintenance of all sample-related metadata and historical records to preserve their original traceability.

Question 29

A newly established biobank, focusing on rare human tissue samples for regenerative medicine research, is undergoing its initial ISO 20387:2018 implementation. The biobank director is concerned about ensuring that all laboratory technicians, data managers, and collection staff are adequately competent to handle sensitive biological materials and associated personal data, especially considering the stringent data protection regulations in their jurisdiction. Which of the following best describes the Lead Implementer\'s primary responsibility in addressing this concern to align with the standard\'s requirements?

Accepted Answer

Developing and overseeing a comprehensive competency framework that includes initial assessment, ongoing training, and periodic re-evaluation of personnel based on their specific biobanking roles and applicable legal requirements.

Question 30

A biobank, established under ISO 20387:2018, is planning to collaborate with an international research consortium. This collaboration involves sharing anonymized human biological samples and associated metadata. The donor consent forms obtained by the biobank explicitly permit the use of samples for \"future research purposes,\" but do not specifically mention international sharing or data transfer to third countries. The biobank\'s Quality Manager is concerned about the legal and ethical implications of this proposed international transfer, particularly regarding data protection and donor rights. Which of the following actions best reflects the biobank\'s responsibility under ISO 20387:2018 to manage this situation effectively?

Accepted Answer

Re-evaluate the existing donor consent to determine if it adequately covers international sharing and data transfer, and if not, implement a process for obtaining updated consent or specific authorizations for this collaboration, ensuring compliance with relevant data protection laws like GDPR if applicable.

ISO 20387:2018 - Biobanking General Requirements Lead Implementer Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 20387:2018 - Biobanking General Requirements Lead Implementer Certification